FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG)
January 31, 2023 13:00 ET
|
Flag Therapeutics, Inc.
RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine...
Glioblastoma Multiforme Treatment Market Is Estimated to Grow at CAGR Of 8.1%, 2022-2029 | Latest Industry Coverage by Douglas Insights
January 11, 2023 03:52 ET
|
Douglas Insights
Isle of Man, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Douglas Insights has added the Global Glioblastoma Multiforme treatment market research to its growing market reports. Douglas Insightsinsights tries...
Recent Advancements in Treatment will help Glioblastoma Treatment Drugs Market to Reach US$ 1.26 Bn at a CAGR of 5.7% Between Forecast Period of 2022-32 | Report by Future Market Insights, Inc.
November 07, 2022 10:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The global glioblastoma treatment drugs market is worth US$ 723.3 Mn as of now and is expected to reach US$ 1.26 Bn by the year 2032 at a CAGR of 5.7%...
Canadian Brain Cancer Patients Treated Unequally: Brain Cancer Canada
October 26, 2022 08:30 ET
|
Brain Cancer Canada
TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- For Canadians diagnosed with brain cancer, where they live determines how much access they have to treatment, according to new research by the charity...
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
October 19, 2022 08:00 ET
|
ITM Isotope Technologies Munich SE
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma patients Garching/Munich, Germany, October 19, 2022 – ITM...
TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study
October 18, 2022 10:07 ET
|
TVAX Biomedical
OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September...
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
September 10, 2022 12:30 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Sept. 10, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced today initial results from a Phase 0 clinical trial of pamiparib in...
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized Care
September 07, 2022 09:00 ET
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced its...
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%, Announced by Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA)
September 06, 2022 07:59 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”....
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung By Over 90% Announced by Ocean Biomedical and Aesther Healthcare (NASDAQ: AEHA)
September 06, 2022 07:45 ET
|
Aesther Healthcare Acquisition Corp.
• Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol,...